The DOI matches its Crossref record; 106 of the 109 references it cites were found in a registry or an index.
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Open accessPublished version of a preprint
Abstract
and RBD epitopes on SARS-CoV-2 spike. Moreover, a 3.4 Å cryo-electron microscopy (cryo-EM) structure of a neutralizing monoclonal Fab-spike complex revealed an epitope that blocks ACE2 receptor binding. Modeling based on these structures suggested different potentials for inter-spike crosslinking by IgGs on viruses, and characterized IgGs would not be affected by identified SARS-CoV-2 spike mutations. Overall, our studies structurally define a recurrent anti-SARS-CoV-2 antibody class derived from VH3-53/VH3-66 and similarity to a SARS-CoV VH3-30 antibody, providing criteria for evaluating vaccine-elicited antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection7,8.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“As expected, plasma neutralizing activity was directly correlated to anti-S and -RBD binding titers in ELISAs7,8 (Fig. 1c, d, and Extended Data Fig. 2a–d).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“In addition, antibodies that share the same combination of IGHV and IGLV genes in vaccinees comprised 39% of all the clonal sequences (Extended Data Fig. 4b) and 59% when combined with naturally infected individuals7,8 (Fig. 2f), and some of these antibodies were nearly identical (Extended Data Table 3 and 4).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“Class 1 and 2 antibodies are among the most potent and also the most abundant antibodies7,8,21,22,25,39.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“Consistent with the plasma neutralization results, the geometric mean neutralization half-maximal inhibitory concentration of the Pfizer-BioNTech and Moderna vaccinee antibodies were not significantly different from each other or to antibody collections obtained from naturally infected individuals 1.3 or 6.2 months after infection (Fig. 3a and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“In anti-RBD ELISAs the mean half-maximal effective concentration (EC50) was higher than that observed in infected individuals after 6.2 months but not significantly different from antibodies obtained 1.3 months after infection (Extended Data Fig. 6a, and Table 5 and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [8]
In the citing paper
“Numerous neutralizing anti-RBD monoclonal antibodies (mAbs) have been characterized, the most potent of which block the RBD-ACE2 interaction (16, 17, 22–24, 32–37).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [32]
In the citing paper
“Antibodies binding to the RBD can potently block attachment of the virus to ACE2 and thereby neutralize the virus”
From SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (2021) · cites this paper as Barnes et al., 2020
In the citing paper
“Their engagement with the RBD is dictated by CDR-H1 and CDR-H2, while the CDR-H3 is characteristically short and makes rather few interactions”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Barnes et al., 2020
In the citing paper
“A number of public antibody responses have been reported for SARS-CoV-2, principal among these being VH3–53/VH3–66 and VH1–58 (VH3–30 is also found, but the antibodies are not potent neutralizers) (Yuan et al., 2020; Barnes et al., 2020; Dejnirattisai et al., 2021).”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Barnes et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Self-citationGuindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., & Gascuel, O. (2010) · Systematic Biology · doi:10.1093/sysbio/syq010 · Cited by 18,376
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega
Sievers, F., Wilm, A., Dineen, D., Gibson, T., Karplus, K., Li, W.-Z., Lopez, R., McWilliam, H., Remmert, M., Söding, J., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.75 · Cited by 15,576
Flagged first, then by citations
3 of the 109 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 803
Mor, M., Werbner, M., Alter, J., Safra, M., Chomsky, E., Lee, J. C., Hada-Neeman, S., Polonsky, K., Nowell, C. J., Clark, A. E., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009165 · Cited by 52
Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern
Voss, C., Esmail, S., Liu, X., Knauer, M. J., Ackloo, S. Z., Kaneko, T., Lowes, L. E., Stogios, P. J., Seitova, A., Hutchinson, A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148855 · Cited by 49
Mechanical activation of spike fosters SARS-CoV-2 viral infection
Hu, W., Zhang, Y., Fei, P., Zhang, T., Yao, D., Gao, Y., Liu, J., Chen, H., Qiao, L., Mudianto, T., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00558-x · Cited by 52
Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain ConformationPreprint
Henderson, R. C., Edwards, R. J., Mansouri, K., Janowska, K., Stalls, V., Kopp, M., Haynes, B. F., & Acharya, P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.173765 · Cited by 49
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
Martinez, D. R., Schäfer, A., Leist, S. R., Li, D., Gully, K. L., Yount, B. L., Feng, J. Y., Bunyan, E., Porter, D., Cihlář, T., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109450 · Cited by 48
Self-citationStructural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM
Saotome, K., Dudgeon, D., Colotti, K., Moore, M. J., Jones, J. L., Zhou, Y., Rafique, A., Yancopoulos, G. D., Murphy, A. J., Lin, J. C.-Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37532-7 · Cited by 56
Montague, Z., Lv, H., Otwinowski, J., DeWitt, W. S., Isacchini, G., Yip, G. K., Ng, W. W., Tsang, O. T.-Y., Yuan, M., Liu, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109173 · Cited by 52
Kim, D. S., Rowland‐Jones, S., & Gea‐Mallorquí, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571481 · Cited by 51
Protective neutralizing epitopes in SARS‐CoV‐2
Liu, H., & Wilson, I. A. (2022) · Immunological Reviews · doi:10.1111/imr.13084 · Cited by 49
On the road to ending the COVID-19 pandemic: Are we there yet?
Case, J. B., Winkler, E. S., Errico, J. M., & Diamond, M. (2021) · Virology · doi:10.1016/j.virol.2021.02.003 · Cited by 47
Zha, L., Chang, X., Zhao, H., Mohsen, M. O., Hong, L., Zhou, Y., Chen, H., Liu, X., Zhang, J., Li, D., et al. (2021) · Vaccines · doi:10.3390/vaccines9040395 · Cited by 49
Sokal, A., Broketa, M., Barba-Spaeth, G., Meola, A., Fernández, I., Fourati, S., Azzaoui, I., de La Selle, A., Vandenberghe, A., Roeser, A., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.002 · Cited by 50
Pushparaj, P., Nicoletto, A., Sheward, D. J., Das, H., Dopico, X. C., Vidakovics, L. P., Hanke, L., Chernyshev, M., Narang, S., Kim, S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.12.005 · Cited by 51
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Cohen, A. A., Keeffe, J. R., Schiepers, A., Dross, S., Greaney, A. J., Rorick, A. V., Gao, H., Gnanapragasam, P. N. P., Fan, C., West, A. P., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.052 · Cited by 51
Self-citationAn Overview of the Crystallized Structures of the SARS-CoV-2
Ionescu, M. I. (2020) · The Protein Journal · doi:10.1007/s10930-020-09933-w · Cited by 50
Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K., Fiala, B., Murphy, M., Pettie, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710263 · Cited by 45
Valdez‐Cruz, N. A., García‐Hernández, E., Espitia, C., Cobos-Marín, L., Altamirano, C., Bando-Campos, C. G., Cofas‐Vargas, L. F., Coronado-Aceves, E. W., González-Hernández, R. A., Hernández‐Peralta, P., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01576-5 · Cited by 52
GlycoGrip: Cell Surface-Inspired Universal Sensor for Betacoronaviruses
Kim, S. H., Kearns, F. L., Rosenfeld, M. A., Casalino, L., Papanikolas, M., Simmerling, C. L., Amaro, R. E., & Freeman, R. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c01080 · Cited by 51
Ku, Z., Xie, X., Lin, J., Gao, P., Wu, B., Sahili, A. E., Su, H., Liu, Y., Ye, X., Tan, E. Y. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33284-y · Cited by 54
Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics
Newby, M. L., Fogarty, C. A., Allen, J. D., Butler, J., Fadda, E., & Crispin, M. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167928 · Cited by 49
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00372 · Cited by 40
Complement Factors in COVID-19 Therapeutics and Vaccines
Kurtovic, L., & Beeson, J. G. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.12.002 · Cited by 47
Knyazev, E. N., Nersisyan, S. A., & Tonevitsky, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636966 · Cited by 47
Cheng, M. H., Krieger, J., Banerjee, A., Xiang, Y., Kaynak, B., Shi, Y., Arditi, M., & Bahar, İ. (2022) · iScience · doi:10.1016/j.isci.2022.103939 · Cited by 50
SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients
Schwarz, T., Heiß, K., Mahendran, Y., Casilag, F., Kurth, F., Sander, L. E., Wendtner, C., Hoechstetter, M. A., Müller, M. A., Sekul, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.629185 · Cited by 45
Prompetchara, E., Ketloy, C., Tharakhet, K., Kaewpang, P., Buranapraditkun, S., Techawiwattanaboon, T., Sathean-anan-kun, S., Pitakpolrat, P., Watcharaplueksadee, S., Phumiamorn, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248007 · Cited by 47
Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
Jaworski, J. P. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.11.011 · Cited by 49
Li, T., Han, X., Gu, C., Guo, H., Zhang, H., Wang, Y., Hu, C., Wang, K., Liu, F., Luo, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26539-7 · Cited by 45
Yang, L., Beek, M. V., Wang, Z., Muecksch, F., Canis, M., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., & Chakraborty, A. K. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112256 · Cited by 50
Self-citationSerapian, S. A., Marchetti, F., Triveri, A., Morra, G., Meli, M., Moroni, E., Sautto, G. A., Rasola, A., & Colombo, G. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c02341 · Cited by 45
Waman, V., Sen, N., Váradi, M., Daina, A., Wodak, S. J., Zoete, V., Velankar, S. S., & Orengo, C. A. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa362 · Cited by 45
Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
Mehra, R., & Kepp, K. P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00433 · Cited by 45
Noval, M. G., Kaczmarek, M. E., Koide, A., Rodriguez-Rodriguez, B. A., Louie, P., Tada, T., Hattori, T., Panchenko, T., Romero, L. A., Teng, K. W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84913-3 · Cited by 53
A highly potent antibody effective against SARS-CoV-2 variants of concern
Fenwick, C. W., Turelli, P., Perez, L. H., Pellaton, C., Esteves-Leuenberger, L., Farina, A., Campos, J., Lana, E., Fiscalini, F., Raclot, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109814 · Cited by 46
Antibody-guided structure-based vaccines
Kwong, P. D., DeKosky, B. J., & Ulmer, J. B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101428 · Cited by 43
A high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-2
Yao, H., Cai, H., Li, T., Zhou, B., Qin, W., Lavillette, D., & Li, D. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009328 · Cited by 46
Targeting protein-protein interaction interfaces in COVID-19 drug discovery
Chang, C., Lin, S., Satange, R., Lin, S., Sun, S.-C., Wu, H., Kehn‐Hall, K., & Hou, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.003 · Cited by 47
Dhar, B. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-03918-7 · Cited by 45
Resende, P. C., Naveca, F. G., Lins, R. D., Dezordi, F. Z., Ferraz, M. V. F., Moreira, E. G., Coêlho, D. F., Motta, F. C., Paixão, A. C. D., Appolinario, L., et al. (2021) · Virus Evolution · doi:10.1093/ve/veab069 · Cited by 47
Abela, I. A., Pasin, C., Schwarzmüller, M., Epp, S., Sickmann, M., Schanz, M., Rusert, P., Weber, J., Schmutz, S., Audigé, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27040-x · Cited by 45
Rossotti, M. A., van Faassen, H., Tran, A., Sheff, J. G., Sandhu, J. K., Duque, D., Hewitt, M., Wen, X., Bavananthasivam, J., Beitari, S., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03866-z · Cited by 45
Liu, Y., Wang, Z., Zhuang, X., Zhang, S., Chen, Z., Zou, Y., Sheng, J., Li, T., Tai, W., Yu, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37926-7 · Cited by 43
50 Years of structural immunology
Wilson, I. A., & Stanfield, R. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100745 · Cited by 44
Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies
Almagro, J. C., Mellado‐Sánchez, G., Pedraza‐Escalona, M., & Pérez‐Tapia, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179763 · Cited by 40
Zhou, T., Tsybovsky, Y., Olia, A. S., Gorman, J., Rapp, M., Cerutti, G., Chuang, G., Katsamba, P. S., Nazzari, A. F., Sampson, J. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.04.187989 · Cited by 48
Riley, T. P., Chou, H., Hu, R., Bzymek, K. P., Correia, A. R., Partin, A. C., Li, D., Gong, D., Wang, Z., Yu, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660198 · Cited by 43
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
Huang, Y., Sun, H., Yu, H. J., Li, S., Zheng, Q., & Xia, N. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa028 · Cited by 40
Kumar, V. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106980 · Cited by 42
Yan, Q., He, P., Huang, X., Luo, K., Zhang, Y., Yi, H., Wang, Q., Li, F., Hou, R., Fan, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1925594 · Cited by 37
Prospects of Neutralizing Nanobodies Against SARS-CoV-2
Chen, F., Liu, Z., & Jiang, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690742 · Cited by 40
Triveri, A., Serapian, S. A., Marchetti, F., Doria, F., Pavoni, S., Cinquini, F., Moroni, E., Rasola, A., Frigerio, F., & Colombo, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00857 · Cited by 38
Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine DosePreprint
Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Tanfous, T. B., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.14.480394 · Cited by 41
Self-citationHanke, L., Sheward, D. J., Pankow, A., Vidakovics, L. P., Karl, V., Kim, C., Urgard, E., Smith, N. L., Astorga-Wells, J., Ekström, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm0220 · Cited by 38
Ford, C. T., Jacob Machado, D., & Janies, D. A. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.830202 · Cited by 52
Valdivia, A., Torres, I., Latorre, V., Francés‐Gómez, C., Albert, E., Gozalbo‐Rovira, R., Alcaráz, M. J., Buesa, J., Rodríguez‐Díaz, J., Geller, R., et al. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04128-8 · Cited by 40
Rouet, R., Henry, J. Y., Johansen, M. D., Sobti, M., Balachandran, H., Langley, D. B., Walker, G. J., Lenthall, H., Jackson, J., Ubiparipovic, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36295-5 · Cited by 41
Generation of Chicken IgY against SARS‐COV‐2 Spike Protein and Epitope Mapping
Lü, Y., Wang, Y., Zhang, Z., Huang, J., Meicun, Y., Huang, G., Ge, Y., Zhang, P., Huang, H., Wang, Y., et al. (2020) · Journal of Immunology Research · doi:10.1155/2020/9465398 · Cited by 40
Malladi, S. K., Patel, U. R., Rajmani, R. S., Singh, R., Pandey, S., Kumar, S., Khaleeq, S., van Vuren, P. J., Riddell, S., Goldie, S., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00276 · Cited by 38
Marconato, M., Abela, I. A., Hauser, A., Schwarzmüller, M., Katzensteiner, R., Braun, D. L., Epp, S., Audigé, A., Weber, J., Rusert, P., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158190 · Cited by 45
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · medRxiv · doi:10.1101/2021.03.07.21253098 · Cited by 41
Wang, K., Cao, Y., Zhou, Y., Wu, J., Jia, Z., Hu, Y., Yisimayi, A., Fu, W., Wang, L., Liu, P., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21261735 · Cited by 40
Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J. C. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., et al. (2021) · doi:10.1101/2021.03.07.434227 · Cited by 39
Self-citationChaudhary, J. K., Yadav, R., Chaudhary, P. K., Maurya, A., Kant, N., Rugaie, O. A., Haokip, H. R., Yadav, D., Roshan, R., Prasad, R., et al. (2021) · Cells · doi:10.3390/cells10112949 · Cited by 42
Fenwick, C. W., Turelli, P., Ni, D., Perez, L. H., Lau, K., Hérate, C., Marlin, R., Lana, E., Pellaton, C., Raclot, C., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01198-6 · Cited by 39
Vaccine design via antigen reorientation
Xu, D., Carter, J. J., Li, C., Utz, A., Weidenbacher, P. A. B., Tang, S., Sanyal, M., Pulendran, B., Barnes, C. O., & Kim, P. S. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01529-6 · Cited by 39
Self-citationChen, X., Rostad, C. A., Anderson, L. J., Sun, H.-Y., Lapp, S. A., Stephens, K., Hussaini, L., Gibson, T., Rouphael, N., & Anderson, E. J. (2021) · Virology · doi:10.1016/j.virol.2021.03.009 · Cited by 44
Emergence and Evolution of a Prevalent New SARS-CoV-2 Variant in the United StatesPreprint
Pater, A. A., Bosmeny, M. S., Barkau, C. L., Ovington, K. N., Chilamkurthy, R., Parasrampuria, M., Eddington, S. B., Yinusa, A. O., White, A. A., Metz, P. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.11.426287 · Cited by 37
Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · doi:10.1101/2021.07.29.454333 · Cited by 275
Self-citationSingh, S., Kaur, R., & Singh, R. K. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01619-8 · Cited by 38
Association of an IGHV3-66 gene variant with Kawasaki disease
Johnson, T. A., Mashimo, Y., Wu, J., Yoon, D., Hata, A., Kubo, M., Takahashi, A., Tsunoda, T., Ozaki, K., Tanaka, T., et al. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-00864-z · Cited by 37
Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 37
Negi, S. S., Schein, C. H., & Braun, W. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-04950-4 · Cited by 35
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
Mlčochová, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Mishra, S., Whittaker, C., Mellan, T. A., Ferreira, I., Datir, R. P., et al. (2021) · Greater South Information System · doi:10.60692/dy28a-h7650 · Cited by 44
Spinello, A., Saltalamacchia, A., Borišek, J., & Magistrato, A. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c01415 · Cited by 32
Yin, V. C., Lai, S., Caniels, T. G., Brouwer, P. J. M., Brinkkemper, M., Aldon, Y., Liu, H., Yuan, M., Wilson, I. A., Sanders, R. W., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00804 · Cited by 36
Windsor, I. W., Tong, P., Lavidor, O., Moghaddam, A. S., McKay, L. G. A., Gautam, A. K., Chen, Y., MacDonald, E. A., Yoo, D. K., Griffths, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo3425 · Cited by 37
Shi, W., Wang, L., Zhou, T., Sastry, M., Yang, E. S., Zhang, Y., Chen, M., Chen, X., Choe, M., Creanga, A., et al. (2022) · Structure · doi:10.1016/j.str.2022.06.004 · Cited by 37
Braet, S. M., Buckley, T. S., Venkatakrishnan, V., Dam, K.-M. A., Björkman, P. J., & Anand, G. S. (2023) · eLife · doi:10.7554/elife.82584 · Cited by 36
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal
Nepali, K., Sharma, R. L., Sharma, S., Thakur, A., & Liou, J. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00847-6 · Cited by 36
Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitroPreprint
Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T. Y., Oren, D. A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.09.288555 · Cited by 35
Self-citationSteffen, T. L., Stone, E. T., Hassert, M., Geerling, E., Grimberg, B. T., Espino, A. M., Pantoja, P., Climent, C., Hoft, D. F., George, S. L., et al. (2020) · doi:10.1101/2020.08.21.261727 · Cited by 25
Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection
Maity, S., & Saha, A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.675419 · Cited by 35
An evidence of microalgal peptides to target spike protein of COVID-19: In silico approach
MubarakAli, D., MohamedSaalis, J., Raghunathan, S., Navabshan, I., & Kim, J. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105189 · Cited by 34
Sariol, C. A., Pantoja, P., Serrano-Collazo, C., Rosa-Arocho, T., Armina-Rodríguez, A., Cruz, L. A., Stone, E. T., Arana, T., Climent, C., Latoni, G., et al. (2021) · Viruses · doi:10.3390/v13101972 · Cited by 31
Jiang, W., Shi, L., Cai, L., Wang, X., Li, J., Li, H., Liang, J., Gu, Q., Ji, G., Li, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110112 · Cited by 33
Innate Immune Response in SARS-CoV-2 Infection
Schiuma, G., Beltrami, S., Bortolotti, D., Rizzo, S., & Rizzo, R. (2022) · Microorganisms · doi:10.3390/microorganisms10030501 · Cited by 39
Silwal, A. P., Thennakoon, S. K. S., Arya, S. P., Postema, R. M., Jahan, R., Phuoc, C. M. T., & Tan, X. (2022) · Theranostics · doi:10.7150/thno.74428 · Cited by 35
Ortega, M. R., Spisak, N., Mora, T., & Walczak, A. M. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010652 · Cited by 34
Structural and functional insights into the evolution of SARS-CoV-2 KP.3.1.1 spike protein
Feng, Z., Huang, J., Baboo, S., Diedrich, J. K., Bangaru, S., Paulson, J. C., Yates, J. R., Yuan, M., Wilson, I. A., & Ward, A. B. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115941 · Cited by 33
Gorchakov, A. A., Kulemzin, S. V., Guselnikov, S. V., Baranov, K. O., Николаевна, Б. Т., Mechetina, L. V., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Chikaev, A. N., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00340-8 · Cited by 33
Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
He, W., Yuan, M., Callaghan, S., Musharrafieh, R. G., Song, G., Silva, M., Beutler, N., Lee, W.-H., Yong, P., Torres, J. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9605 · Cited by 32
A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics
Verma, J. K., & Subbarao, N. (2021) · Archives of Virology · doi:10.1007/s00705-021-04961-y · Cited by 32
Zhou, X., Ma, F., Xie, J., Yuan, M., Li, Y., Shaabani, N., Zhao, F., Huang, D., Wu, N. C., Lee, C.-C. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109109 · Cited by 31
Chevillard, C., Amen, A., Besson, S., Hannani, D., Bally, I., Dettling, V., Gout, E., Moreau, C., Buisson, M., Gallet, S., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.011 · Cited by 35
Jacob-Dolan, C., Feldman, J. E., McMahan, K., Yu, J., Zahn, R. C., Wegmann, F., Schuitemaker, H., Schmidt, A. G., & Barouch, D. H. (2021) · Journal of Virology · doi:10.1128/jvi.00117-21 · Cited by 32
B Cell Responses upon Human Papillomavirus (HPV) Infection and Vaccination
Prabhu, P. R., Carter, J. J., & Galloway, D. A. (2022) · Vaccines · doi:10.3390/vaccines10060837 · Cited by 34
Ultrasensitive detection of SARS-CoV-2 spike protein by graphene field-effect transistors
Silvestri, A., Zayas-Arrabal, J., Vera‐Hidalgo, M., Silvio, D. D., Wetzl, C., Moro, M. M., Zurutuza, A., Torres, E., Centeno, A., Caro, A. M., et al. (2022) · Nanoscale · doi:10.1039/d2nr05103f · Cited by 30
Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
Sheward, D. J., Pushparaj, P., Das, H., Greaney, A. J., Kim, C., Kim, S., Hanke, L., Hyllner, E., Dyrdak, R., Lee, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101577 · Cited by 31
Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidatesPreprint
Walser, M., Rothenberger, S., Hurdiss, D. L., Schlegel, A., Calabro, V., Fontaine, S., Villemagne, D., Paladino, M., Hospodarsch, T., Neculcea, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.256339 · Cited by 30
Metadata
- Authors
- Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Finkin, S., Hägglöf, T., Hurley, A., Millard, K. G., Weisblum, Y., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Caskey, M., Robbiani, D. F., Nussenzweig, M. C., & Bjorkman, P. J.
- Affiliations
- California Institute of Technology (US)
- Rockefeller University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Nussenzweig, Michel C.
- ORCID
- Barnes, Christopher O.
- West, Anthony P.
- Hoffmann, Magnus A.G.
- Sharaf, Naima G.
- Hoffman, Pauline R.
- Koranda, Nicholas
- Gristick, Harry B.
- Gaebler, Christian
- Muecksch, Frauke
- Lorenzi, Julio C. Cetrulo
- Finkin, Shlomo
- Hägglöf, Thomas
- Hurley, Arlene
- Millard, Katrina G.
- Weisblum, Yiska
- Schmidt, Fabian
- Bieniasz, Paul D.
- Caskey, Marina
- Robbiani, Davide F.
- Nussenzweig, Michel C.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 182
- Issue
- 4
- Pages
- 828-842.e16
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC7311918
- OpenAlex
- W3036607916
- Cited by
- 795
- References
- 109
- Citations by year
- 2026: 34 · 2025: 49 · 2024: 50 · 2023: 84 · 2022: 151 · 2021: 319 · 2020: 107
- FWCI
- 21.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cell (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by-nc-nd)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- National Center for Advancing Translational Sciences (UL1 TR001866)
- Burroughs Wellcome Fund
- Howard Hughes Medical Institute
- Basic Energy Sciences (DE-AC02-76SF00515)
- National Institute of General Medical Sciences (P41GM103393, 2U19AI111825, P50 8 P50 AI150464-13, P01-AI138938-S1)
- Bill and Melinda Gates Foundation (INV-002143)
- Office of Science
- Biological and Environmental Research
- U.S. Department of Energy
- Beckman Institute, California Institute of Technology
- George Mason University
- California Institute of Technology
- National Institutes of Health
- Rockefeller University
- Icahn School of Medicine at Mount Sinai
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2 spike protein, human antibodies, neutralizing antibodies, ACE2 binding, IgG, spike protein mutations, vaccine-elicited antibodies, antibody structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
